Carlsmed, Inc. (CARL) vs Neurogene Inc. (NGNE)
A side-by-side comparison of Carlsmed, Inc. and Neurogene Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CARL
Carlsmed, Inc.
$14.76HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
NGNE
Neurogene Inc.
$25.44HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
Total return — CARL vs NGNE
growth of $100 · dividends reinvested · last 1yCARL +5.5% (+5.5%/yr)NGNE +20.6% (+20.6%/yr)NGNE compounded faster over this window
CARL NGNE
CARL vs NGNE: by the numbers
- •NGNE is the larger company ($402M vs $401M market cap).
- •Both run net losses; NGNE's is the smaller (0.00% vs -57.42% net margin).
Metrics side by side
Valuation
| Metric | CARL | NGNE |
|---|---|---|
| P/S ratio | 6.34 | N/A |
| P/B ratio | 4.76 | 1.85 |
Profitability
| Metric | CARL | NGNE |
|---|---|---|
| Gross margin | 76.63% | 0.00% |
| Operating margin | -61.09% | 0.00% |
| Net margin | -57.42% | 0.00% |
| ROE | -43.14% | -51.17% |
| ROIC | -36.54% | -54.45% |
Growth (annualized)
| Metric | CARL | NGNE |
|---|---|---|
| Total return CAGR (5Y) | N/A | -27.73% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.